Investors
-
September 14, 2022 Non RegulatoryUmecrine Cognition secures funding ahead of Phase 2 study of golexanolone in patients with primary biliary cholangitisSTOCKHOLM – September 14, 2022. Umecrine Cognition today announces that the company has secured funding of SEK 41 million for the start of a Phase...
-
August 10, 2022 Non RegulatoryUmecrine Cognition announces the recruitment of Anders Karlsson as new CEOSOLNA – August 10, 2022. Umecrine Cognition AB today announces that its Board of Directors has appointed Anders Karlsson as new CEO. He succeeds...
-
July 7, 2022 Non RegulatoryNotice to attend Extraordinary General Meeting in Umecrine Cognition ABThe shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the extraordinary general meeting at 10:00 a.m. on...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.